Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2006

Modulation of the Serotonin Reuptake Transporter in RAW264.7
Macrophages
Sienna Marie Arenas Malubay
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Biology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/706

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

O Sienna Marie A. Malubay
All Rights Reserved

2006

Modulation of the Serotonin Reuptake Transporter in RAW264.7 Macrophages

A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science at Virginia Commonwealth University

BY
Sienna Marie Arenas Malubay
B.S. Biology
The College of William and Mary, Williamsburg, Virginia
2003

Director: Jennifer K. Stewart, Ph.D.
Associate Professor, Department of Biology

Virginia Commonwealth University
Richmond, Virginia
May 2006

Acknowledgment

I would like to express my gratitude to the people whose support has made the
completion of this project possible. First and foremost, I would like to thank Dr. Jennifer
Stewart for being a wonderful mentor and for allowing me to work in her laboratory.
During my time in the lab, she has been an unvarying source of knowledge and
encouragement. I would also like to thank Dr. Krista Fischer-Stenger for teaching me all

I know about Western Blots and for her support and friendship. In addition, I would like
to thank my committee members Dr. Michael Fine, Dr. Robert Tombes, and Dr. Joseph
Porter for their time and participation in this endeavor.
I would also express my gratitude to the members of the Neuroendocrinology
laboratory, both past and present: Meghan Rudd, Kristie Engler, Christopher Waggener,
Shauntii Poe, George Georges, Neal Bhatia, and Omar Noor. Your friendship and help in
the lab have been invaluable over the past two years. I would also like to thank Amy
Seneca1 of the Stenger Lab at University of Richmond for her help with Western Blots,
Lin Zhang of the Zhou Lab (VCU) for his help with MTT assays, and Mohit Kashyap of
the Ryan Lab (VCU) for providing CTMC lysates. I also owe my heartfelt appreciation
to my friends here at VCU and beyond.
Last, but definitely not least, I would like to thank my family, especially my
parents, Oscar and Mila Malubay, and my sister, Hosannah, for their support and love
throughout my academic career. I could not have done it without you.

Table of Contents

Acknowledgment .................................................................................................................

..

11

List of Tables .......................................................................................................................
v
List of Figures .....................................................................................................................
vi
...
. .
List of Abbrevlatlons ........................................................................................................
vlll

Abstract ..............................................................................................................................
xi
Introduction ..........................................................................................................................
1
2
Serotonin and its receptors .......................................................................................
Macrophages ...........................................................................................................
-3
Serotonin and the Immune System ..........................................................................
5
Function and regulation of the SERT...................................................................... 6
Methods and Materials .......................................................................................................
10
RAW 264.7 Macrophages ......................................................................................
10
Recruited Macrophages .........................................................................................
10
Uptake of 3H-5HT Assay .......................................................................................
11
Western Blotting ....................................................................................................
12
MTT Cell Viability Assay .....................................................................................

13

Measurement of TNF-a and IL-l(3........................................................................14
RNA Isolation ........................................................................................................ 14
...

111

iv
Reagents .................................................................................................................
15
Data Analyses ........................................................................................................ 15
Results ................................................................................................................................ 16
Comparison of 3

~

- uptake
5 ~in RAW264.7
~
macrophages and peritoneal

macrophages .......................................................................................................... 16
LPS activation of RAW264.7 macrophages increased SERT activity .................. 16
LPS modulation of SERT activity was time- and concentration-dependent ......... 17
IL- 10 decreased 5-HT uptake ................................................................................ 18
Mechanism for SERT upregulation by LPS .......................................................... 18
Discussion ..........................................................................................................................21
List of References .............................................................................................................. 24
Appendix: Figures and Tables ........................................................................................... 33
Vita ..................................................................................................................................... 48

List of Tables

Table.............................................................................................................................Page
1. Summary of serotonin receptor families and their effects............................................34

List of Figures

Figure.. ............................................................................................,..............................Page

1. Biosynthesis pathway of serotonin from L-tryptophan ................................................33
2. Summary of SERT Regulation .....................................................................................35

3. Comparison of total, specific, and non-specific uptake of 'H-~HTby RAW264.7
macrophages. ..............................................................................................................-36
4. LPS-activation increases sodium dependent uptake of 3 ~ - 5 H in
T RAW264.7
macrophages ................................................................................................................37

5. NaCl dependence of 'H-~HTuptake in RAW264.7 macrophages............................... 38
6A. Effects of fluoxetine on specific uptake of 'H-5HT in vehicle-treated
RAW264.7 macrophages .............................................................................................39

6B. Kinetics of fluoxetine inhibition of 'H-~HTuptake in vehicle-treated RAW264.7
macrophages.. ........................................................................................... . ................39

7A. Effects of fluoxetine on specific uptake of 'H-SHT in LPS-treated
RAW264.7 macrophages.. ........................................................,..................................40

7B. Kinetics of fluoxetine inhibition of 3

~

-uptake
5 ~in LPS-treated
~
RAW264.7

macrophages.. ..............................................................................................................40

vii

8. Time-dependent effects of LPS activation on specific uptake of 3

~

-

5

~

~

in RAW264.7 macrophages.. .......................................................................................41

9. Concentration-dependent effects of LPS activation on specific uptake of 3

~

- in 5

RA W264.7 macrophages.. ...........................................................................................42

10A. Effects of IL-10 on specific uptake of 3

~

- in 5vehicle-treated
~ ~
and

LPS-treated RAW264.7 macrophages .........................................................................43

10B. Viability of RAW264.7 macrophages after treatment with vehicle
(media alone), LPS, andlor IL- 10................................................................................43

11. IL-10 modulation of 3

~

- specific
5 ~ uptake
~
in RAW264.7 macrophages treated with

a low (optimal) concentration of LPS ..........................................................................44

12. Expression of SERT protein in RAW264.7 macrophages assayed by
Western blotting ........................................................................................................... 45

13. Inhibition of guanylyl cyclase by LY83583 in RAW264.7 macrophages ..................46
14A. Extracellular concentrations of TNF-a in RAW264.7 macrophages .......................47
14B. Extracellular concentrations of IL-1 P in RAW264.7 macrophages .........................47

~

~

List of Abbreviations

3

~

. .

-...........................................................................................
5 ~ ~
tntium-labeled serotonin

5-HT..................................................................................
5-hydroxytryptamine (serotonin)
..5-hydroxytrytophan
5-HTP.............................................................................................
5-HTR .......................................................................................................
serotonin receptor
ANOVA ................................................................................................. analysis of variance
CAMP............................................................................cyclic adenosine 5'-monophosphate
cGMP...........................................................................cyclic guanosine 5'-monophosphate
CFA ..........................................................................................complete Freund's Adjuvant
CNS ...................................................................................................central nervous system
.dopamine
D A.. .......................................................................................................................
DAG.. ..............................................................................................................diac ylgl ycerol
DAT.. ..................................................................................................
dopamine transporter
Epi ...................................................................................................................... .epinephrine
GMP ........................................................................................guanosine 5'-monophosphate
GC.. ............................................................................................................

g u a n l 1 c yclase

GI ........................................................................................................... gastrointestinal tract
HRP.. ................................................................................................. horseradish peroxidase
...

Vlll

ix
IFNy.. .........................................................................................................interferon gamma
IgG ...........................................................................................................immunoglobulin G

IL- 1....................................................................................................................interleukin- 1

IL- 10................................................................................................................interleukin-10
IL- 12................................................................................................................interleukin-1 2
IL- 16............................................................................................................... .interleukin- 16
IP3..........................................................................................................i n o s t o triphosphate
LiCl. ..............................................................................................................lithium chloride
LPS ......................................................................................................... .lipopolysaccharide
LY83583. ...........................................................................6-anilinoquinoline-5,8-quinone
MAPK ................................................................................mitogen-activated protein kinase
MTT ....................................3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide
NaCl ............................................................................................................. sodium chloride
NE. .................................................................................................................norepinephrine
NET .............................................................................................norepinephrine transporter
. .
NO .......................................................................................................................n t c oxide

NOS ....................................................................................................n i t oxide synthetase
OCT 1........................................................................................organic cation transporter 1
OCT 2 .....................................~

i cation transporter 2

OCT 3........................................................................................
organic cation transporter 3

c

X

PBS ...............................................................................................phosphate buffered saline

PCR .............................................................................................. polymerase chain reaction
PD 169316......................4-(4-fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole
PDE5 ......................................................................................................
phosphodiesterase 5
PKA .............................................................................................................protein kinase A
PKC ..........................................................................................................p r o t e i n lunase C
PKG .............................................................................................................

. .
protein lunase G

PNS ..............................................................................................peripheral nervous system
PP2A ................................................................................................
protein phosphatase 2A
RT-PCR ...................................................... reverse transcriptase polymerase chain reaction
SERT......................................................................................serotonin reuptake transporter
SH.................................................................................................................... sucrose hepes
SNARE.............................................................................. soluble NSF attachment receptor
SSRI............................................................................selective serotonin reuptake inhibitor
SynlA................................................................................................................. syntaxin 1A
TBST.............................................................................Tris-buffered saline with Tween-20
TCA ................................................................................................... tricyclic antidepressant
TNF-a .........................................................................................

tumor necrosis factor alpha

VMAT ............................................................................... vesicular monoamine transporter

Abstract

MODULATION OF THE SEROTONIN REUPTAKE TRANSPORTER IN RAW264.7
MACROPHAGES

Sienna Marie Arenas Malubay, B.S.

A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2006

Major Director: Jennifer K. Stewart, Ph.D., Associate Professor, Department of Biology

Serotonin (5-HT) plays an important role as both a neurotransmitter and an
immune modulator. The serotonin reuptake transporter (SERT) clears the extracellular
space of 5-HT, which decreases the effects of 5-HT on target cells.

This study

demonstrated that the RAW264.7 macrophage cell line expresses SERT function,
measured by assays of 3

~

- uptake.
5 ~ The
~ 5-HT uptake in RAW264.7 macrophages

was more than 10-fold that of peritoneal macrophages, indicating that these cells are an
excellent model for studying regulation of the SERT. Activation of macrophages with

xii
lipopolysaccharide (LPS) increased SERT activity in a time- and concentrationdependent manner and Western blots indicate that the increase in activity is partially due
to LPS-induced increases in total SERT protein. Both unstimulated and LPS-stimulated
activity was inhibited by the specific SERT inhibitor fluoxetine (ICSo= 5-8 nM) and was
reduced by the anti-inflammatory cytokine interleulun-10.

Changes in extracellular

concentrations of interleulun-lp and tumor necrosis factor-a did not affect SERT activity.

Introduction

Monoamines, which include dopamine (DA), epinephrine (Epi), norepinephrine
(NE), and serotonin (5-hydroxytryptamine; 5-HT), are found in the central nervous
system (CNS) as well as the periphery. These molecules serve as neurotransmitters,
hormones, and paracrine regulators and are synthesized at many sites.
Monoamines are transported across the plasma membrane by either Type I
neuronal or Type I1 extra-neuronal transporters. The Type I transporters are sodiumdependent and include the dopamine transporter (DAT), the norepinephrine transporter
(NET), and serotonin transporter (SERT). All of these transporters have more than one
substrate. For instance, the NET has a two-fold higher affinity for NE than for Epi but
transports both across the cell membrane (12). These Type I transporters are generally
inhibited by cocaine. Though called the neuronal transporters, the Type I transporters
also are found in non-neuronal cells. The Type I1 extra-neuronal transporters include
members of the organic cation transporter family (OCT1, OCT2, and OCT3) (12). The
Type I1 transporters have an affinity for a broad range of substrates. OCT3 also has been
called the extra-neuronal monoamine transporter (EMT) (12). These Type I1 transporters
usually are inhibited by catecholamine metabolites, such as metanephrine (2; 12).
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Serotonin and its receptors:
Serotonin (5-HT) is an indolamine derived from the amino acid tryptophan. Ltryptophan is converted to 5-hydroxytryptophan (5-HTP) by tryptophan 5-hydroxylase.
Next, 5-HTP is converted to 5-HT by 5-HTP decarboxylase (Figure 1) (10).
Serotonin is made primarily by serotonergic neurons found in the midbrain and
medulla of the mammalian central nervous system (CNS) and in the enterochromaffin
cells of the gastrointestinal tract (GI). In the CNS, vesicles in pre-synaptic neurons store
5-HT until released into the synapse. Once in the synaptic cleft, 5-HT can bind to its
receptors on post-synaptic neurons. Similarly, in the periphery, 5-HT is released into the
extracellular space in order to bind to its receptors. While synthesized primarily by
enterochromaffin cells outside of the CNS, 5-HT also can be picked up and stored by
many different non-neuronal cells, such as platelets and mast cells, for later release (29).
Seven families of 5-HT receptors (5-HT1.7)have been identified to date. Some of
these receptors also have subtypes and have been classified by their structure, function,
and pharmacology (16). The many subtypes of the 5-HT1 receptor family are coupled to
Gi/Go proteins. Generally these receptors mediate a decrease in the concentration of
cyclic adenosine 5'-monophosphate (CAMP) in the cytosol through the inhibition of
adenylyl cyclase, or the receptors mediate opening of potassium ion (Kf) channels to
hyperpolarize the neuron (13). These receptors affect cerebral vasoconstriction, neuronal
inhibition, and behavioral effects, such as sleep, thermoregulation, and anxiety. Whereas
the members of the 5-HT1 receptor family are generally found in the CNS, the three
members of the 5-HT2 family are found in both the CNS and periphery. These G,/Gll-

coupled proteins increase the amount of inosotol triphosphate (IP3) and diacylglycerol
(DAG) found in the cell and affect neuronal excitation, smooth muscle contraction, and
platelet aggregation (13). The 5-HT3 receptor is a serotonin-gated sodiurn/potassium
(Na+/K+)channel that is found in both the CNS and peripheral nervous system (PNS). It
stimulates rapid depolarization of the plasma membrane, which in turn leads to neuronal
excitation and anxiety (13). Both the 5-HT4 receptor and 5-HT7 receptors are G,-coupled
proteins that function in the CNS and GI tract by increasing the levels of CAMPavailable
within the cell. The 5-HT4 receptor affects neuronal excitation and may have a role in
peristalsis (16). Not much is known about the effects of the 5-HT7 receptor, though it
may have a role in mood, learning, neuroendocrine, and vegetative disorders (16).
Although the 5-HT5 and 5-HT6 receptors have been identified, little is known about them
(see Table 1 for summary).

Macrophages:
Macrophages are mononuclear phagocytes that play an important role in both
innate and acquired immunity. Pluripotent hematopoietic stem cells from bone marrow
can differentiate into monocytes, the precursor of macrophages.

Monocytes travel

throughout the body in the circulatory system. Through the process of extravasation,
monocytes leave the blood vessels and develop into tissue-resident macrophages.
Macrophages are the first line of defense in the innate immune system. They are
one of the first cells to appear at the site of injury or infection and work to clear the area
of pathogens and debris through phagocytosis. Bacteria or other pathogens are ingested
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by macrophages in a phagosome, which later binds to a lysozome containing digestive
enzymes to break down the ingested material (21). In addition, macrophages produce
reactive oxygen species, such as nitric oxide. These are released at the site of infection in
an oxidative burst and kill invading pathogens (21).
Macrophages

synthesize

cytokines

in

response

to

stimuli,

such

as

lipopolysaccharide (LPS), a component of the cell wall of gram-negative bacteria. The
pro-inflammatory cytokines (TNF-a, IL-ID, IL-6, IL-8, and IL-12) released by
macrophages further develop and coordinate the immune response (21). These cytokines,
along with other chemotactic factors secreted by the macrophage, work to further activate
the macrophage, as well as other immune cells, and signal additional immune cells to the
site of infection (21; 30). The macrophage also produces anti-inflammatory cytokines
such as IL-10 that counteract the pro-inflammatory cytokines, and the macrophage
functions in the acquired immune response as an antigen-presenting cell. After bacteria
have been digested, an antigen fragment is bound to the macrophage's major
histocompatibility (MHC) class I1 molecule and is brought to the plasma membrane. The
helper T cells then bind to the MHC-II+antigen complex with its CD4 protein (44).
Previous studies indicate that macrophages take up monoamines, such as the
catecholamine NE (2; 20). Recently in our lab, Meghan Rudd showed that the SERT,
which transports DA as well as serotonin, is functional in mouse peritoneal macrophages
(40).

5
Serotonin and the Immune System:

The role of 5-HT as a CNS neurotransmitter has been extensively studied, but its
role in the periphery is not as well known. Serotonin has been shown to affect a variety
of systems in the body. In the cardiovascular system, for example, 5-HT works as a
vasoconstrictor, and in the digestive system, 5-E-IT stimulates smooth muscle
contractions, such as peristalsis (13; 29). Serotonin also affects many of the cells in the
immune system.
Different types of 5-HT receptors are found on many immune cells. Recently,
mRNA for serotonin receptor subtypes lE, 2A, 3, 4 and 7 ( 5 - m R I E ,5-HTRZA,5-HTR3,
5-HTR4, and 5-HTR7) have been found in monocytes (1 1). Serotonin induces the release
of chemotactic factors, such as IL-16, by peripheral blood mononuclear cells (26). In
addition, 5-HT has a role in delayed-type hypersensitivity (for review: (29)).
Serotonin also has been shown to affect macrophage phenotype and function. For
example, in mice treated with para-chlorphenylalanine (pCPA), a tryptophan hydroxylase
inhibitor, the resulting 5-HT depletion decreased splenic macrophage activation of Tcells (29; 46). Moreover, 5-HT, acting through the 5-HTIAreceptor, upregulates the
macrophage's phagocytic activity (14).

In addition, 5-HT can modulate cytokine

production in macrophages. For example, serotonin inhibits the production of LPSinduced TNF-a in macrophages in a dose-dependent manner (1). Although high levels of
5-HT can reduce IL-6 and TNF-a production, depletion of 5-HT with pCPA also
decreases the production of IL-6 and TNF-a (25). Similar effects are observed on the
production of pro-inflammatory cytokine IFN-y and the anti-inflammatory cytokine IL-

10 (24).
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These findings suggest that low concentrations of 5-HT are needed for

production of these cytokines, but high levels of 5-HT are inhibitory (24; 25).

In

addition, 5-HT-induced increases in the production of IL-6, IL-1P, and IL-8 appear to be
mediated by 5-HT4 and 5-HT7receptors (1 1).
Furthermore, 5-HT may play a role in lipid storage in monocytes, which are
precursors of macrophages. Suguro et al. have found that 5-HT causes an increase in the
expression of the acyl-coenzymeA:cholesterol acyltransferase-1 (ACAT-1) protein in
monocytes (42). ACAT-1 changes free cholesterol into cholesterol esters for storage.
The storage of lipids in macrophages leads to the formation of foam cells, which
participate in the formation of atherosclerotic plaque (27).

Function and regulation of the SERT:

The serotonin reuptake transporter (SERT) is a protein with twelve membranespanning domains (4). It is found on many different cell types including neurons,
platelets, mast cells, and macrophages.

The SERT takes up 5-HT, decreasing its

concentration in the synapse or extracellular space, which decreases the interaction of 5HT with 5-HT receptors (18).
Changes in SERT function have been implicated in several neurological diseases
including clinical depression and obsessive-compulsive disorders (32; 45). As such, the
pharmacology of the SERT has been examined thoroughly. It is the target of many
antidepressants, such as the selective serotonin reuptake inhibitors (SSRIs) including
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fluoxetine (prozacB), and is modulated by less specific uptake inhibitors, such as tricyclic
antidepressants and cocaine (4; 45).
The SERT gene is a member of a large family made up of transporters genes, such
as the NET gene and DAT gene (4; 43). All of the transporters are Na'ICl- dependent
and can be blocked by cocaine (2; 4; 37). Specifically, the SERT cotransports 5-HT with
Na' and C1- ions into the cell while transporting K' ions into the extracellular space.
Voltage clamp studies indicate that Na', C1-, and 5-HT bind to the SERT inducing a
conformational change that allows them to enter the cytosolic space. Once this exchange
has been made, K' binds to a site on the SERT causing it to return to the original
conformation and allowing K+ to exit into the extracellular space (6; 36).
Many recent studies have investigated SERT regulation. SERT has been shown
to interact with the SNARE protein syntaxin 1A (SynlA) (17), and treatment with
botulinum C1 toxin, which cleaves SynlA, causes a decrease in SERT function in
thalamacortical neurons (36).
Other laboratories have examined the role of phosphorylation on the expression
and function of the SERT. Protein phosphatase 2A (PP2A) interacts with the SERT and
down-regulate its activity (38). The SERT also is readily phosphorylated by protein
kinase A (PKA) and protein lunase C (PKC). Whereas increased PKA phosphorylation
has little effect on activity, increased phosphorylation with PKC causes a downregulation of 5-HT transport by the SERT (5). In addition, PKC works in a biphasic
manner in its regulation of the SERT. Activated PKC phosphorylates the SERT serine
residues within 5 min, inhibiting the SERT (23).

After 30 min, activated PKC
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phosphorylates SERT threonine residues, causing SERT endocytosis and further
inhibition of its activity (23). Moreover, amphetamines, cocaine, and a variety of SERT
substrates, such as 5-HT, modulate PKC-dependent SERT phosphorylation and modulate
surface distribution (22; 37).
Protein kinase G (PKG) and p38 mitogen-activated protein lunase (MAPK) play a
role in up-regulating SERT activity (34; 41; 48-50). The inhibition of p38 MAPK by
PD 169316 (4-(4-fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole) has shown
that p38 MAPK is necessary for maintaining SERT function (41). There is now evidence
that p38 MAPK up-regulates the SERT through PP2A. Although p38 MAPK and PP2A
activate the SERT, these enzymes do not regulate insertion of the SERT into the plasma
membrane (48). In contrast, PKG promotes an increase of SERT surface density (49).
Treatment with sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, causes a rise in
cGMP, which increases SERT activity and density (50). Adenosine, acting through the
adenosine receptor, appears to up-regulate SERT activity via this pathway (49). Figure 2
summarizes major pathways regulating the SERT

The SERT has been extensively studied in the CNS or in transfected cells, but
little studied in other cell types in which this protein is naturally expressed. Nevertheless,
Meghan Rudd in our laboratory found that recruited peritoneal macrophages express
SERT mRNA as well as functional protein (40). Furthermore, using reverse transcriptase
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PCR (RT-PCR) our laboratory has revealed that the RAW264.7 macrophage cell-line

also expresses SERT mRNA (39). In the study presented here, we examined the
regulation of SERT activity within this cell line.

Methods and Materials

RA W264.7 Macrophages
Murine macrophages from the RAW264.7 cell line (American Type Cell Culture,
Manassas, VA) were cultured in complete RPMI containing RPMI-1640 (Gibco brand,
Invitrogen, Carlsbad, CA) with 10% heat-inactivated fetal bovine serum (Cellgro brand,
VWR, West Chester, PA), 1% L-glutamine, 1% minimal essential medium vitamins, 1%
nonessential amino acids, 100 Unitslml penicillin, 100 pglml streptomycin, and 10 mM
HEPES buffer at pH 7.4 (Gibco brand, Invitrogen, Carlsbad, CA). The cell cultures were
maintained at 37 "C in 5% C 0 2 in 75 cm2 tissue culture flasks (Corning brand, Fisher
Scientific, Hampton, NH). The cultures were sub-cultured twice weekly.

Recruited Macrophages

Female CBAIJ mice (6-8 weeks of age) were obtained from Harlan (Indianapolis,
IN) and housed in the Virginia Commonwealth University animal facilities under the
guidelines of the University Animal Care and Use Committee.

Macrophages were

recruited via an intraperitoneal injection with 0.5 ml of a 1:1 complete Freund's Adjuvant
(CFA; Sigma-Aldrich, St. Louis, MO) and phosphate buffered saline (PBS; Gibco brand,
Invitrogen, Carlsbad, CA). After two weeks, the mice were euthanized with COz. The
10
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recruited peritoneal macrophages were harvested, washed with Hank's Balanced Salt
Solution (Gibco brand, Invitrogen, Carlsbad, CA) and allowed to adhere for 4 h in 12well tissue culture plates (Costar brand, Fisher Scientific, Hampton, NH). Non-adherent
cells were discarded, and adherent cells were washed with complete RPMI and treated
with vehicle (media alone) or activated with lipopolysaccharide (LPS; E. coli serotype
055:B5; Sigma-Aldrich, St. Louis, MO). The macrophages were maintained in complete
RPMI at 37 "C in 5% C 0 2 for the times designated in each experiment.

Uptake of ~ H - S H T~ s s q
RAW264.7 macrophages were plated in 12-well tissue culture plates (1.5 x lo6
cellslwell) and were treated as designated in each experiment. The plates were incubated
at 37 "C in 5% C 0 2 overnight, allowing the cells to grow to a density of approximately 3
x lo6 cellslwell. The uptake assay is a modification of Ganapathy et al. (15), Horschitz et
al. (19), and Rudd et al. (40).
Immediately prior to the assay, the cells were washed twice with 1 ml of roomtemperature sucrose Hepes (SH) uptake buffer containing 140 mM NaCl (LiCl or choline
chloride for certain experiments), 2 mM KCl, 1 mM CaC12, 1 mM MgC12, 5 mM glucose,
10 mM Hepes (pH 7.4), and 320 rnM sucrose. The macrophages were then preincubated
for 5 min with SH uptake buffer containing 250 yM ascorbic acid (Sigma-Aldrich, St.
Louis, MO), 10 yM pargyline (Sigma-Aldrich, St. Louis, MO), and vehicle or various
concentrations of inhibitors.

Radiolabeled serotonin (25 nM, 18 Cilmmol; Vitrax,

Placentia, CA) was added, and incubation continued for 10 min (except in time course
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experiments). All incubations were conducted at room temperature. The uptake buffer
was removed, and cells were washed twice with 2 ml of SH buffer. The cells were lysed
with 800 p1 of 0.2 N NaOH containing 1% SDS, and the lysate was transferred to 10 ml
of Scintisafe scintillation fluid (Fisher Scientific, Hampton, NH). The wells were washed
with an additional 600 p1 of the NaOHISDS (Sigma-Aldrich, St. Louis, MO), and the
wash was transferred to the scintillation fluid.

Radioactivity was measured with a

Beckman LS6000IC scintillation counter (Beckrnan Coulter, Inc., Fullerton, CA).

Western Blotting

Cultured cells were lysed with 100-300 p1 of ice cold buffer containing 0.05 M
Tris (pH 7.5), 0.3 M NaCl, 2 mM EDTA, 1% Triton-X 100, 2 pglml leupeptin, 1 pglml
aprotinin, and 0.2 mM phenylmethylsulfonyl fluoride. Lysate protein concentrations
were determined with the BioRad protein assay (BioRad Laboratories, Hercules, CA).
Proteins (50 pg, or 30 pg for connective-tissue-derived mast cells) were separated
by SDS-PAGE on 10% polyacrylamide gels (BioRad Laboratories, Hercules, CA). The
separated proteins were transferred via electroblotting to nitrocellulose membranes
(BioRad Laboratories, Hercules, CA) and incubated 1 h at room temperature in a
blocking solution of 500 ml Tris-buffered saline containing 0.1% Tween-20 (TBST) and
3% dry milk. The membranes were then incubated overnight at 4 OC with either goat
anti-mouse SERT (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or rabbit anti-rat
SERT (Chemicon, Temecula, CA) diluted 1:500. The membranes were washed three
times with TBST, and then incubated with either a 1:5000 dilution of donkey anti-goat
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IgG conjugated with horseradish peroxidase (HRP) or goat anti-rabbit IgG-HRP (Santa
Cruz Biotechnology, Inc). The membranes were washed four times with TBST, and
enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ) was used to
visualize immunoreactive proteins.
To control for loading of protein, blots were stripped with Restore Stripping
Buffer (Pierce Biotechnology, Inc., Rockford, IL) and reprobed for p-actin by incubating
1 h with a 1:5000 dilution of mouse monoclonal anti-p-actin (Sigma-Aldrich, St. Louis,
MO), then washed with TBST. The membrane was incubated with a 1:5000 dilution of
HRP-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)
before washing and visualizing with enhanced chemiluminescence (Amersham
Biosciences, Piscataway, NJ).

MTT Cell Viability Assay
The MTT assay protocol is an adaptation of Mosmann (28), Carmichael et al. (7),
and Pozzolini et al. (33). RAW264.7 macrophages were plated in 12-well cell culture
plates (Costar brand, Fisher Scientific, Hampton, NH) at a density of 1.5 x lo6 cells/well.
The cells were treated with vehicle (media alone) or LPS (30 nglml) and incubated at 37
"C in 5% C 0 2 for 24 h. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-dipheny1tetrazo1ium
bromide; Sigma-Aldrich, St. Louis, MO) was added to each well at a final concentration
of 0.5 mglml and incubated for an additional 4 h. All media was then aspirated, and cells
were lysed with a buffer containing sodium dodecyl sulfate (SDS; Sigma-Aldrich, St.
Louis, MO) dissolved in 50% N,N-dimethyl-formamide (DMF; Sigma-Aldrich, St. Louis,
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MO) and incubated overnight at 37 "C. The plate was read with the pQuant Universal
Microplate Reader (Bio-Tek Instruments, Winooski, VT) at 570 nm.

Measurement of TNF-a and IL-Ip
Extracellular TNF-a and IL-6 concentrations were assayed with the OptEIA Multi
Component ELISA Set for Mouse TNF-a and Mouse IL-IP, respectively (BD
Biosciences, San Diego, CA).

The assays were performed in accordance with the

manufacturer's protocols. The plates were read at 450 and 570 nm with a pQuant
Universal Microplate Spectrophotometer (BioTek Instruments, Winooski, VT). TNF-a
and IL-1P concentrations were calculated with KC4 software (BioTek Instruments,
Winooski, VT).

RNA Isolation
RAW264.7 macrophages were cultured in 6-well tissue culture plates (Costar
brand, Fisher Scientific, Hampton, NH) and treated with vehicle (media alone) or LPS
(30 nglml) as designated per experiment. Total RNA was extracted from approximately
six million cells in culture with TRI-Reagent (Molecular Research Center, Cincinnati,
OH) according to the procedures provided by the manufacturer. RNA samples were
stored at -70 "C.

Reagents

Fluoxetine used in 3

~

- uptake
5 ~assays
~ was a gift from Eli Lilly (Indianapolis,

IN). All other reagents, including IL-10 and unlabeled 5-HT, were purchased from
Sigma-Aldrich (St. Louis, MO).

Data Analyses

Analysis of variance (ANOVA) and Tukey's multiple comparison test were used
to evaluate effects of transport inhibitors and cytokines on 3

~

- uptake.
5 ~ ICS0
~ values

were calculated with Prism software (Graphpad, San Diego, CA). For experiments with
only two treatments, a t-test was used to compute statistical significance. Differences
were considered statistically significant at p10.05.

Results

Comparison of 3

~

-uptake
5 ~in RA
~ W264.7 macrophages and peritoneal macrophages

To calculate specific uptake of 3 ~ - 5the~ non-specific
~ ,
uptake, measured in the
presence of 25 pM non-radioactive 5HT, was subtracted from the total uptake of 3

~

-

(Figure 3). The specific uptake of 'H-SHT in RAW264.7 macrophages was surprisingly
high.

Uptake of 'H-~HT, measured over 10 min, in these cells was 21-fold that

previously measured in mouse peritoneal macrophages (40) and approximately 11 times
that measured in primary peritoneal macrophages in this study (Figure 4). In this study,
primary cells were incubated with twice the concentration of 3

~

- used
5 in
~ either
~

assays of RAW264.7 cells or previous assays of primary cells.

LPS activation of RA W264.7 macrophages increased 5-HT uptake
Lipopolysaccharide (LPS) activation of RAW264.7 macrophages stimulated a
2.5-fold increase of 'H-~HTspecific uptake compared to 3 ~ - 5 H specific
T
uptake in cells
treated with media alone (vehicle) (Figure 5). Moreover, specific uptake was sodium
dependent in both vehicle- and LPS-treated macrophages (Figure 5).

When pre-

incubated with SH uptake buffer containing either lithium chloride (LiCl) or choline

5

~

~
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chloride, uptake was inhibited more than 90% compared to uptake by macrophages
incubated in SH uptake buffer containing NaCl. LPS did not significantly affect uptake
measured in LiCl or choline chloride buffer.
In order to verify the role of the SERT in the uptake of 5-HT in RAW264.7
macrophages, 3

~

- uptake
5 ~ assays
~
in the presence of the SSRI fluoxetine were

performed (Figures 6A and 7A). In both vehicle- and LPS-treated macrophages, uptake
of 3

~

- was
5 reduced
~ ~ as the concentration of fluoxetine was increased. The IC50 of

fluoxetine inhibition was 5.7 nM for 5-HT transport in vehicle-treated macrophages
(Figure 6B) and 7.7 nM in LPS-treated cells (Figure 7B). These IC50 values are similar to
those reported for the SERT in mouse peritoneal macrophages and in human cells (3; 40).

LPS modulation of SERT activity was time- and concentration-dependent

Up-regulation of SERT activity by LPS activation was time-dependent (Figure 8).
RAW264.7 macrophages were treated with vehicle (media only) or 30 ng/ml LPS and
incubated at 4 h, 12 h, or 24 h prior to assay of 3

~

- uptake.
5 ~ At~ 4 h and 12 h after

treatment, there was no significant difference in SERT activity in vehicle-treated and
LPS-treated cells. At 24 h after LPS (30 ng/ml), SERT activity increased approximately
2.3-fold compared to SERT activity in vehicle-treated cells.
Although we have routinely used 30 - 50 nglml LPS to activate macrophages, and
30 nglml LPS was used in initial experiments, a concentration-response curve revealed
that 3

~

- specific
5 ~ uptake
~
peaked when cells were treated with 1

-

3 ng/ml LPS
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(Figure 9). Treatment with 1 ng/ml or 3 ng/ml LPS elevated SERT activity in the
macrophages by approximately 3.3 times compared to vehicle-treated cells.

IL-10 decreased 5-HT uptake
When the anti-inflammatory cytokine interleukin- 10 (IL-10; 20 ng/ml) was added
to the cell media 2 h prior to treatment with vehicle or LPS (26 h before measurement of
3

~

- uptake),
5 ~ SERT
~
activity decreased by approximately 45% in vehicle-treated cells

and 61% in LPS-treated cells (Figure 10A). An MTT (3-(4,5-dimethylthiazol-2-y1)-2,5diphenyltetrazolium bromide) viability assay demonstrated no significant differences in
cell viability that could account for the differences in SERT activity observed 24 h after
vehicle, LPS (30 ng/ml), or IL-10 (20 ng/ml) (Figure 10B). Furthermore, IL-10 (20
ng/ml) also inhibited SERT activity roughly 41% in macrophages activated with low
levels of LPS (3 ng/ml) (Figure 1I).

Mechanism for SERT upregulation by LPS
Western blotting was used to determine whether LPS increased SERT protein in
RAW264.7 macrophages (Figure 12). Connective tissue mast cells (CTMC), a positive
control, produced a distinct band at approximately 70 kDa as expected (8; 35). No
immunoreactive SERT was observed in L929 fibroblasts, which served as the negative
control. The estimated molecular weight of immunoreactive SERT detected in both
vehicle- and LPS-treated RAW264.7 lysates was 75 kDa, whereas the kDa of the SERT
in CTMC was 70 kDa. Interestingly, the density of immunoreactive SERT from LPS-
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treated RAW264.7 macrophages was greater than that in the vehicle-treated cells (n=3)
suggesting that LPS increased total SERT protein; however, the differences were not
statistically significant. In order to determine if LPS also increases SERT mRNA, RNA
samples have been extracted and frozen for future real-time PCR analysis.
LPS-activated macrophages produce nitric oxide (NO), which activates the SERT
through the PKGIp38 MAPK pathway (for review: see Figure 2)(48-50). To investigate
whether PKG is involved in the LPS-induced upregulation of SERT activity, the 3

~

-

uptake assay was performed in the presence of LY83583, a guanylyl cyclase (GC)
inhibitor (Figure 11). As expected, there was a significant increase in 5-HT uptake in
cells treated with LPS (30 nglml) compared to those treated with media only (vehicle).
When vehicle- or LPS-treated cells were incubated with LY83583 (10 pM) or its
appropriate vehicle (0.1% ethanol) for 24 h, the inhibitor killed the cells (data not
shown). When cells were treated with LPS or vehicle for 24 h and incubated with the
inhibitor for 20 min prior to the 3

~

- uptake
5 ~ assay,
~
there were no significant

differences between those incubated with LY83583 and those without LY83583. These
findings suggest that short-term inhibition of GC does not affect SERT activity in
RAW264.7 macrophages, although others have demonstrated short-term effects of this
inhibitor on the SERT in other cells (49).
LPS-activated macrophages release pro-inflammatory cytokines such as tumor
necrosis-alpha (TNF-a) and interleukin- 1g (IL- 10). Preliminary data from enzyrnelinked immunosorbent assays (ELISA) indicated that there is more TNF-a (1.3-fold) and
IL-1P (6.3-fold) present in the cell media of cells treated with 30 nglml LPS than those

5

~

~
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treated with 1 nglml LPS (Figure 14A and 14B). Yet, the lower concentration of LPS is
the optimal stimulus for SERT activity.

Despite evidence that TNF-a and IL-1P

stimulate increased SERT activity in some cell types (47), these preliminary data suggest
that these cytokines are not the only stimulus for 5-HT during macrophage activation.

Discussion

This study demonstrates that RAW264.7 macrophages express high SERT
activity, more than 10-fold that observed in peritoneal macrophages in this study or in
previous studies in our laboratory (40). Therefore, this cell line is an excellent model for
studying regulation of the SERT.
This study shows for the first time that SERT activity is increased by LPSinduced activation of macrophages in a time- and concentration-dependent manner.
Because more than 12 h of LPS activation is required to detect increased SERT activity,
it is probable this rise in 5-HT uptake is not due simply to a translocation of the SERT
protein. Moreover, Zhu et al. suggest that PKG plays a role in the exocytosis of the
SERT protein from vesicles in the cytosol to the plasma membrane (49); however, assay
of 3

~

- uptake
5 ~ in ~the presence of a PKG inhibitor, LY83583, failed to significantly

decrease SERT activity. Western blotting suggested that there was more SERT protein
present in LPS-activated macrophages than in vehicle-treated cells.

Conversely,

previously we were unable to detect effects of LPS on SERT protein in recruited
peritoneal macrophages (40), although recruitment may have maximally stimulated
SERT activity prior to LPS treatment.
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The mechanism for IL-10-induced reduction of SERT activity in this study is
unknown, but it has been shown that IL-10 can work through the STAT3 pathway in
order to decrease proliferation of macrophages (31). Using an MTT viability assay,
however, we could not find any significant change in cell viability induced by IL-10 (20
ng/ml) and LPS (30 ng/ml). It is conceivable, however, that high concentrations of LPS
(90 ng/ml) do not increase SERT activity because cell viability is reduced.
Because the pro-inflammatory cytokines stimulate p38 MAPK activity, it is not
surprising that these cytokines also increase SERT activity (9). For example, TNF-a and
IL-1P, pro-inflammatory cytokines, have been shown to stimulate 5-HT uptake in a rat
embryonic neuronal cell line and in midbrain synaptosomes through the p38 MAPK
pathway (47). Data from our lab, however, show that more TNF-a is secreted by
RAW264.7 macrophages at higher concentrations of LPS, and the increase in 5-HT
uptake peaks at approximately 1 ng/ml LPS. These findings suggest that while proinflammatory cytokines play a role in the LPS-stimulation of the SERT, there may be
additional stimulation through other pathways.
In summary, this study demonstrates that the RAW264.7 macrophage cell line is a
useful model system to study the SERT and its regulation. Moreover, this is the first
study to demonstrate that LPS-activation of macrophages increases SERT activity. These
findings may have clinical implications in patients taking SSRIs such as fluoxetine
(prozacQ), sertraline (zoloftQ), and paroxetine (paxilB). As these SSRIs inhibit SERT
activity, there are higher concentrations of extracellular 5-HT, allowing for increased
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binding to 5-HT receptors. This may lead to an increase in the actions caused by the of

5-HT on macrophages such as decreased production of TNF-a (25).
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